(Q33376440)

26 July 2017

Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

1 reference

Norihito Soga

1

1 reference

26 July 2017

Takehisa Onishi

series ordinal

2

1 reference

26 July 2017

Kiminobu Arima

series ordinal

3

1 reference

26 July 2017

Yoshiki Sugimura

series ordinal

4

1 reference

26 July 2017

1 September 2007

1 reference

International Journal of Urology

26 July 2017

1 reference

26 July 2017

14

1 reference

26 July 2017

9

1 reference

26 July 2017

828-832

1 reference

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

26 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01831.X

Update on chemotherapy for advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01831.X

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01831.X

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01831.X

Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01831.X

Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01831.X

Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01831.X

Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01831.X

Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01831.X

Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01831.X

Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01831.X

10.1111/J.1442-2042.2007.01831.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference